EUVIMEDEUVIMED entdecken
Crossref

Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy

Zhijie Wang, HaiQi He, Xiaotong Liao, Lin Yuan, Shuding Sun, Chenglong Xu, Xixiang Yang, Qinru Zang, Xiaopeng Peng iD, Jianjun Chen iD, Xia Guo

Journal of Medicinal Chemistry · 24.04.2025 · 68 (8) · 8046-8064

DOI: 10.1021/acs.jmedchem.4c02529 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 15.04.2025. Verfasst von Zhijie Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Shenzhen Key Laboratory of Viral Oncology, Ministry of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen 518100, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Histone Deacetylase Inhibitors, Immunotherapy, Histone Deacetylases. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Southern Medical University, Science, Technology and Innovation Commission of Shenzhen Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenHistone Deacetylase InhibitorsImmunotherapyHistone DeacetylasesAntineoplastic AgentsImmune Checkpoint InhibitorsDrug DiscoveryAnimalsHumansMiceCell Line, TumorStructure-Activity RelationshipMice, Inbred C57BLMelanoma, ExperimentalHistone Deacetylase 3

Substanzen

B7-H1 AntigenHistone Deacetylase InhibitorsHistone DeacetylasesAntineoplastic AgentsImmune Checkpoint InhibitorsHistone Deacetylase 3CD274 protein, human

Autor:innen und Institutionen

  • Shenzhen Key Laboratory of Viral Oncology, Ministry of Science and Innovation, Shenzhen Hospital, Southern Medical University, Shenzhen 518100, China.
  • School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China.
  • Academy of Chinese Medicine Sciences, Henan University of Chinese Medicine, Zhengzhou, Henan 450046, China.
  • Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, Key Laboratory for Tissue Engineering of Jiangxi Province, School of Pharmacy, Gannan Medical University, Ganzhou 341000, PR Chi…

ORCID-Profile: Xiaopeng Peng, Jianjun Chen

Förderung

  • China Postdoctoral Science Foundation
  • Southern Medical University
  • Science, Technology and Innovation Commission of Shenzhen Municipality
  • Organization Department of the Central Committee of the Communist Party of China
  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Innovation Program
  • Shenzhen Key Laboratory of Viral Oncology
  • Research Foundation of Shenzhen Hospital of Southern Medical University

Zitieren

APA

Wang, Z., He, H., Liao, X., Yuan, L., Sun, S., Xu, C., Yang, X., Zang, Q., Peng, X., Chen, J., & Guo, X. (2025). Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy. Journal of Medicinal Chemistry, 68(8), 8046-8064. https://doi.org/10.1021/acs.jmedchem.4c02529

Vancouver

Wang Z, He H, Liao X, Yuan L, Sun S, Xu C, et al. Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy. Journal of Medicinal Chemistry. 2025;68(8):8046-8064. doi:10.1021/acs.jmedchem.4c02529

BibTeX
@article{Wang2025,
  author = {Wang, Zhijie and He, HaiQi and Liao, Xiaotong and Yuan, Lin and Sun, Shuding and Xu, Chenglong and Yang, Xixiang and Zang, Qinru and Peng, Xiaopeng and Chen, Jianjun and Guo, Xia},
  title = {Discovery of Dual PD-L1/HDAC3 Inhibitors for Tumor Immunotherapy},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {8},
  pages = {8046--8064},
  doi = {10.1021/acs.jmedchem.4c02529}
}
Kostenlos starten →